| scholarly article | Q13442814 |
| P2093 | author name string | Elizabeth M Lamos | |
| Lisa M Younk | |||
| Stephen N Davis | |||
| P2860 | cites work | The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys | Q31112204 |
| U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients | Q33602161 | ||
| Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region | Q34085107 | ||
| Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria | Q34269828 | ||
| Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml | Q34543063 | ||
| Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. | Q34583341 | ||
| New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). | Q35240456 | ||
| New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). | Q35538347 | ||
| Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects | Q35563634 | ||
| Durability of glycemic control using U-500 insulin | Q35783956 | ||
| Clinical use of U-500 regular insulin: review and meta-analysis | Q36051311 | ||
| Low within- and between-day variability in exposure to new insulin glargine 300 U/ml | Q36361469 | ||
| Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes | Q36366184 | ||
| Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study | Q57951497 | ||
| Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia | Q72874429 | ||
| Successful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitus | Q74070281 | ||
| Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart | Q80119501 | ||
| Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes | Q84440683 | ||
| Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective | Q87006980 | ||
| Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus | Q87413740 | ||
| New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1 | Q87643980 | ||
| One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten | Q36366198 | ||
| Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension | Q36730246 | ||
| How hypoglycaemia can affect the life of a person with diabetes | Q37035202 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). | Q37106467 | ||
| Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta | Q37106509 | ||
| Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials | Q37119978 | ||
| Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials | Q37321746 | ||
| High-dose insulin therapy: is it time for U-500 insulin? | Q37391062 | ||
| Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment | Q37506417 | ||
| Insulin degludec: pharmacokinetics in patients with renal impairment | Q37506526 | ||
| Fear of hypoglycaemia in adults with Type 1 diabetes. | Q37790425 | ||
| U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients | Q37899649 | ||
| Clinical experience with U500 insulin: risks and benefits | Q37908817 | ||
| Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir | Q38073204 | ||
| Are you ready for more insulin concentrations? | Q38266858 | ||
| Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. | Q39421962 | ||
| Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy | Q40914196 | ||
| Clinical efficacy and patient satisfaction with U-500 insulin use. | Q42100513 | ||
| Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. | Q42240405 | ||
| A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance | Q43115619 | ||
| New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). | Q44485772 | ||
| Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes | Q44533647 | ||
| A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec | Q44599380 | ||
| The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients | Q44631767 | ||
| The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes | Q45893987 | ||
| Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). | Q46247786 | ||
| Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action | Q46358093 | ||
| Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden | Q46967505 | ||
| Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis | Q48487507 | ||
| Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes | Q49174475 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 389-400 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Concentrated insulins: the new basal insulins | |
| P478 | volume | 12 |
| Q64904369 | Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective. |
| Q64239470 | Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment |
| Q52606010 | Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements. |
| Q92100367 | Glargine-300: An updated literature review on randomized controlled trials and real-world studies |
| Q47621392 | Hypoglycemia Reduction Strategies in the ICU. |
| Q92550113 | Insulin Initiation and Titration in Patients With Type 2 Diabetes |
| Q41006286 | Microfabrication for Drug Delivery |
| Q92188767 | Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL |
| Q44372707 | Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions |
| Q41963319 | Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach |
Search more.